HRMY NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Harmony Biosciences Holdings · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 35.24 USD
-0.2% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 8.4% above the Trend Line and sits at 63.3% of its 52-week range. The latest completed week returned -0.2%, after a -5.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers. Options positioning is volatility with 57/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 1d.

Setup score 40 out of 100
Latest Close 35.24 USD 31 Jul 2026
1W Return -0.2% latest completed week
4W Return -5.4% short-term follow-through
12W Return 13.7% quarterly tape
Trend Breadth 28.8% 15 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 1-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 42.66% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.2% Latest completed week; four-week move -5.4%. Indicator stack 19/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.66% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 57/100 conviction; expected move 14.7%. News sentiment 57/100 56 relevant articles in the latest sentiment read. Event risk 1d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 8.4% above the Trend Line and sits at 63.3% of its 52-week range. The latest completed week returned -0.2%, after a -5.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5712-week average 0.27

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.57Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.4% over four weeks, 13.7% over 12 weeks, and 2.4% over one year. The current trend has remained active for 1 consecutive weeks.

Performance by holding period

1W-0.2%
4W-5.4%
12W13.7%
26W-3.5%
52W2.4%
Active trend streak1 weeks
Active weeks in one year15
Trend breadth28.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.80Latest activity-pressure read.
Pressure change-14.2%Four-week change in activity pressure.
Leadership-2.46Latest relative-leadership reading.
RS change-8.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 92%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength92/100Blend of value, momentum, and quality. Underlying universe rank 9; rank 1 is best.
Value90/100Relative valuation strength. Underlying universe rank 11; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum35/100Medium-term price momentum. Underlying universe rank 66; rank 1 is best.
Growth69/100Revenue and earnings growth. Underlying universe rank 32; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
14.0x
Price divided by trailing earnings.
Price / sales
2.3x
Market value relative to trailing revenue.
EV / EBITDA
7.1x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
20.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
76.5%
Gross profit retained from each unit of revenue.
Operating margin
23.1%
Operating profit retained from revenue.
Free-cash-flow margin
38.1%
Free cash flow generated from revenue.
Return on invested capital
29.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
20.7%
Latest one-year revenue growth.
EPS growth
-4.7%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
52.8%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.3%
Net share repurchases relative to market value.
Shareholder yield
-0.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

HRMY shows volatility options pressure with a 57/100 conviction score, put-call volume ratio of 36.67, expected move of 14.7%, and Sharemaestro trend signal active.

Conviction57/100
Expected move14.7%
Put/call volume36.67
Pressure-95
Speculation23
Volatility85
Trend agreement12
Open options detail
Insider activity8 / 2

8 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 56 relevant articles.

19 positive · 33 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings1dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move14.7%Nearest-chain priced movement where available.
52-week drawdown-13.8%Distance below the 52-week high.
13-week volatility4.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+7.0%Week of 12 Jun.
Worst week-19.0%Week of 20 Feb.
Latest week-0.2%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains7
Flat weeks0
Modest losses9
Sharp losses3
Recent vol4.4%13-week weekly-return volatility.
Base vol6.1%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -4.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape38/100

Trend, activity pressure, participation, and risk combine to a 38/100 tape read.

 Indicator analysis38/100

Latest 12-week confirmation: trend 1/12, activity pressure 10/12, relative leadership 0/12.

Activity pressure 0.57; No reversal markers Next-Week ExpectancyNegative 42.66%

Next-week expectancy is negative with a 42.66% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors80/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 74; Small Cap Core rank 33 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options40/100

HRMY shows volatility options pressure with a 57/100 conviction score, put-call volume ratio of 36.67, expected move of 14.7%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 14.7% Sentiment57/100

Weighted news tone is neutral across 56 relevant articles.

Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings Insiders8 / 2

8 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings1d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202635.24 USD-0.2%32.51 USD32.81 USD0.80-2.463.2MOn
24 Jul 202635.32 USD4.6%32.58 USD32.80 USD0.95-2.105.3MOff
17 Jul 202633.77 USD-8.3%32.67 USD32.79 USD0.96-8.394.7MOff
10 Jul 202636.84 USD-1.1%32.81 USD32.81 USD0.92-4.713.4MOff
3 Jul 202637.26 USD5.0%32.93 USD32.80 USD0.94-2.263.8MOff
26 Jun 202635.47 USD6.6%33.01 USD32.77 USD0.84-6.354.3MOff
19 Jun 202633.28 USD-3.4%33.01 USD32.77 USD0.72-16.342.9MOff
12 Jun 202634.46 USD7.0%33.04 USD32.79 USD0.58-11.554.9MOff
5 Jun 202632.20 USD1.9%33.03 USD32.80 USD0.29-15.904.1MOff
29 May 202631.59 USD4.8%33.00 USD32.82 USD0.11-21.813.2MOff
22 May 202630.15 USD0.2%32.90 USD32.84 USD-0.08-23.853.1MOff
15 May 202630.09 USD-2.9%32.91 USD32.87 USD-0.07-23.753.5MOff
8 May 202630.99 USD-2.6%32.77 USD32.91 USD-0.20-22.405.1MOff
1 May 202631.83 USD3.3%32.62 USD32.94 USD-0.40-16.672.8MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.